Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases
Immunomagnetic reduction (IMR), which involves the use of antibody-functionalized magnetic nanoparticles to specifically label target biomarkers, was utilized to develop an assay for total tau protein in human plasma. The analytic properties of the IMR assay on tau protein were investigated. The lim...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2017-08, Vol.7 (1), p.9304-12, Article 9304 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 12 |
|---|---|
| container_issue | 1 |
| container_start_page | 9304 |
| container_title | Scientific reports |
| container_volume | 7 |
| creator | Yang, Shieh-Yueh Chiu, Ming-Jang Chen, Ta-Fu Lin, Chin-Hsien Jeng, Jiann-Shing Tang, Sung-Chun Lee, Yen-Fu Yang, Che-Chuan Liu, Bing-Hsien Chen, Hsin-Hsien Wu, Chau-Chung |
| description | Immunomagnetic reduction (IMR), which involves the use of antibody-functionalized magnetic nanoparticles to specifically label target biomarkers, was utilized to develop an assay for total tau protein in human plasma. The analytic properties of the IMR assay on tau protein were investigated. The limit of detection was found to be 0.026 pg/ml. Other properties such as Hook effect, assay linearity, dilution recovery range, reagent stability, interference test, and spiked recovery were also characterized. The ultra-sensitive IMR assay was applied to detect the plasma tau protein levels of subjects with prevalent neurodegenerative diseases, such as Alzheimer’s disease (AD), mild cognitive impairment (MCI) due to AD, Parkinson’s disease (PD), frontotemporal dementia (FTD) and vascular dementia (VD). The concentrations of plasma tau protein in patients with VD, PD, MCI due to AD, FTD, and AD patients were higher than that of healthy controls. Using an ROC curve analysis, the cutoff value for discriminating dementia patients from healthy controls was 17.43 pg/ml, resulting in 0.856 and 0.727 for clinical sensitivity and specificity, respectively. The area under the ROC curve was 0.908. These results imply that the IMR plasma tau assay would be useful to screen for prevalent neurodegenerative diseases. |
| doi_str_mv | 10.1038/s41598-017-09009-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5571227</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1932846658</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-b758d4f4346ad71c0c78ff1293ed99ca98ffe8ae51f219552ac476d3346cdb4d3</originalsourceid><addsrcrecordid>eNp1kduKFDEQhhtR3GXdF_BCAt5405pjd-dGWBZPsOCNXoeapHo2S3cyJt0L8wC-tzXOuoyCIeRUX_1J5W-al4K_FVwN76oWxg4tF33LLee2VU-ac8m1aaWS8unJ-qy5rPWOUzPSamGfN2dyGJQVXX_e_LxKMO2X6GFiOyxjLjMkjyyPrCBsMS2MzhjUCvuYtmyBle1KXjAmRv12JZztJqgzMEiBjQg1buIUlz2ryxpo9AUxHXITriUHJFEssMR7ZCFW4rG-aJ6NMFW8fJgvmu8fP3y7_tzefP305frqpvW610u76c0Q9KiV7iD0wnPfD-MopFUYrPVgaYcDoBGjFNYYCZTXBUW8Dxsd1EXz_qi7WzczBk_lFZjcrsQZyt5liO7vSIq3bpvvnTG9kLIngTcPAiX_WLEubo7V4zRBwrxWJ6ySg-46MxD6-h_0Lq-FfvtAmV5x8kcQJY-UL7nWguPjYwR3B6Pd0WhHRrvfRjtFSa9Oy3hM-WMrAeoIVAqlLZaTu_8v-wvyz7fU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1957300451</pqid></control><display><type>article</type><title>Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases</title><source>MEDLINE</source><source>Nature Free</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature OA Free Journals</source><creator>Yang, Shieh-Yueh ; Chiu, Ming-Jang ; Chen, Ta-Fu ; Lin, Chin-Hsien ; Jeng, Jiann-Shing ; Tang, Sung-Chun ; Lee, Yen-Fu ; Yang, Che-Chuan ; Liu, Bing-Hsien ; Chen, Hsin-Hsien ; Wu, Chau-Chung</creator><creatorcontrib>Yang, Shieh-Yueh ; Chiu, Ming-Jang ; Chen, Ta-Fu ; Lin, Chin-Hsien ; Jeng, Jiann-Shing ; Tang, Sung-Chun ; Lee, Yen-Fu ; Yang, Che-Chuan ; Liu, Bing-Hsien ; Chen, Hsin-Hsien ; Wu, Chau-Chung</creatorcontrib><description>Immunomagnetic reduction (IMR), which involves the use of antibody-functionalized magnetic nanoparticles to specifically label target biomarkers, was utilized to develop an assay for total tau protein in human plasma. The analytic properties of the IMR assay on tau protein were investigated. The limit of detection was found to be 0.026 pg/ml. Other properties such as Hook effect, assay linearity, dilution recovery range, reagent stability, interference test, and spiked recovery were also characterized. The ultra-sensitive IMR assay was applied to detect the plasma tau protein levels of subjects with prevalent neurodegenerative diseases, such as Alzheimer’s disease (AD), mild cognitive impairment (MCI) due to AD, Parkinson’s disease (PD), frontotemporal dementia (FTD) and vascular dementia (VD). The concentrations of plasma tau protein in patients with VD, PD, MCI due to AD, FTD, and AD patients were higher than that of healthy controls. Using an ROC curve analysis, the cutoff value for discriminating dementia patients from healthy controls was 17.43 pg/ml, resulting in 0.856 and 0.727 for clinical sensitivity and specificity, respectively. The area under the ROC curve was 0.908. These results imply that the IMR plasma tau assay would be useful to screen for prevalent neurodegenerative diseases.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-017-09009-3</identifier><identifier>PMID: 28839167</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/378/340 ; 631/61/32 ; 9/10 ; Aged ; Aged, 80 and over ; Alzheimer's disease ; Cognitive ability ; Dementia ; Dementia disorders ; Diagnostic Tests, Routine - methods ; Feasibility Studies ; Frontotemporal dementia ; Humanities and Social Sciences ; Humans ; Mass Screening - methods ; Middle Aged ; Movement disorders ; multidisciplinary ; Nanoparticles ; Neurodegenerative diseases ; Neurodegenerative Diseases - diagnosis ; Parkinson's disease ; Plasma ; Plasma - chemistry ; Proteins ; ROC Curve ; Science ; Science (multidisciplinary) ; Sensitivity and Specificity ; Sexually transmitted diseases ; STD ; Tau protein ; tau Proteins - blood ; Vascular dementia</subject><ispartof>Scientific reports, 2017-08, Vol.7 (1), p.9304-12, Article 9304</ispartof><rights>The Author(s) 2017</rights><rights>2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-b758d4f4346ad71c0c78ff1293ed99ca98ffe8ae51f219552ac476d3346cdb4d3</citedby><cites>FETCH-LOGICAL-c474t-b758d4f4346ad71c0c78ff1293ed99ca98ffe8ae51f219552ac476d3346cdb4d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571227/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571227/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,41096,42165,51551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28839167$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Shieh-Yueh</creatorcontrib><creatorcontrib>Chiu, Ming-Jang</creatorcontrib><creatorcontrib>Chen, Ta-Fu</creatorcontrib><creatorcontrib>Lin, Chin-Hsien</creatorcontrib><creatorcontrib>Jeng, Jiann-Shing</creatorcontrib><creatorcontrib>Tang, Sung-Chun</creatorcontrib><creatorcontrib>Lee, Yen-Fu</creatorcontrib><creatorcontrib>Yang, Che-Chuan</creatorcontrib><creatorcontrib>Liu, Bing-Hsien</creatorcontrib><creatorcontrib>Chen, Hsin-Hsien</creatorcontrib><creatorcontrib>Wu, Chau-Chung</creatorcontrib><title>Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Immunomagnetic reduction (IMR), which involves the use of antibody-functionalized magnetic nanoparticles to specifically label target biomarkers, was utilized to develop an assay for total tau protein in human plasma. The analytic properties of the IMR assay on tau protein were investigated. The limit of detection was found to be 0.026 pg/ml. Other properties such as Hook effect, assay linearity, dilution recovery range, reagent stability, interference test, and spiked recovery were also characterized. The ultra-sensitive IMR assay was applied to detect the plasma tau protein levels of subjects with prevalent neurodegenerative diseases, such as Alzheimer’s disease (AD), mild cognitive impairment (MCI) due to AD, Parkinson’s disease (PD), frontotemporal dementia (FTD) and vascular dementia (VD). The concentrations of plasma tau protein in patients with VD, PD, MCI due to AD, FTD, and AD patients were higher than that of healthy controls. Using an ROC curve analysis, the cutoff value for discriminating dementia patients from healthy controls was 17.43 pg/ml, resulting in 0.856 and 0.727 for clinical sensitivity and specificity, respectively. The area under the ROC curve was 0.908. These results imply that the IMR plasma tau assay would be useful to screen for prevalent neurodegenerative diseases.</description><subject>631/378/340</subject><subject>631/61/32</subject><subject>9/10</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer's disease</subject><subject>Cognitive ability</subject><subject>Dementia</subject><subject>Dementia disorders</subject><subject>Diagnostic Tests, Routine - methods</subject><subject>Feasibility Studies</subject><subject>Frontotemporal dementia</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Mass Screening - methods</subject><subject>Middle Aged</subject><subject>Movement disorders</subject><subject>multidisciplinary</subject><subject>Nanoparticles</subject><subject>Neurodegenerative diseases</subject><subject>Neurodegenerative Diseases - diagnosis</subject><subject>Parkinson's disease</subject><subject>Plasma</subject><subject>Plasma - chemistry</subject><subject>Proteins</subject><subject>ROC Curve</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Sensitivity and Specificity</subject><subject>Sexually transmitted diseases</subject><subject>STD</subject><subject>Tau protein</subject><subject>tau Proteins - blood</subject><subject>Vascular dementia</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kduKFDEQhhtR3GXdF_BCAt5405pjd-dGWBZPsOCNXoeapHo2S3cyJt0L8wC-tzXOuoyCIeRUX_1J5W-al4K_FVwN76oWxg4tF33LLee2VU-ac8m1aaWS8unJ-qy5rPWOUzPSamGfN2dyGJQVXX_e_LxKMO2X6GFiOyxjLjMkjyyPrCBsMS2MzhjUCvuYtmyBle1KXjAmRv12JZztJqgzMEiBjQg1buIUlz2ryxpo9AUxHXITriUHJFEssMR7ZCFW4rG-aJ6NMFW8fJgvmu8fP3y7_tzefP305frqpvW610u76c0Q9KiV7iD0wnPfD-MopFUYrPVgaYcDoBGjFNYYCZTXBUW8Dxsd1EXz_qi7WzczBk_lFZjcrsQZyt5liO7vSIq3bpvvnTG9kLIngTcPAiX_WLEubo7V4zRBwrxWJ6ySg-46MxD6-h_0Lq-FfvtAmV5x8kcQJY-UL7nWguPjYwR3B6Pd0WhHRrvfRjtFSa9Oy3hM-WMrAeoIVAqlLZaTu_8v-wvyz7fU</recordid><startdate>20170824</startdate><enddate>20170824</enddate><creator>Yang, Shieh-Yueh</creator><creator>Chiu, Ming-Jang</creator><creator>Chen, Ta-Fu</creator><creator>Lin, Chin-Hsien</creator><creator>Jeng, Jiann-Shing</creator><creator>Tang, Sung-Chun</creator><creator>Lee, Yen-Fu</creator><creator>Yang, Che-Chuan</creator><creator>Liu, Bing-Hsien</creator><creator>Chen, Hsin-Hsien</creator><creator>Wu, Chau-Chung</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170824</creationdate><title>Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases</title><author>Yang, Shieh-Yueh ; Chiu, Ming-Jang ; Chen, Ta-Fu ; Lin, Chin-Hsien ; Jeng, Jiann-Shing ; Tang, Sung-Chun ; Lee, Yen-Fu ; Yang, Che-Chuan ; Liu, Bing-Hsien ; Chen, Hsin-Hsien ; Wu, Chau-Chung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-b758d4f4346ad71c0c78ff1293ed99ca98ffe8ae51f219552ac476d3346cdb4d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>631/378/340</topic><topic>631/61/32</topic><topic>9/10</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer's disease</topic><topic>Cognitive ability</topic><topic>Dementia</topic><topic>Dementia disorders</topic><topic>Diagnostic Tests, Routine - methods</topic><topic>Feasibility Studies</topic><topic>Frontotemporal dementia</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Mass Screening - methods</topic><topic>Middle Aged</topic><topic>Movement disorders</topic><topic>multidisciplinary</topic><topic>Nanoparticles</topic><topic>Neurodegenerative diseases</topic><topic>Neurodegenerative Diseases - diagnosis</topic><topic>Parkinson's disease</topic><topic>Plasma</topic><topic>Plasma - chemistry</topic><topic>Proteins</topic><topic>ROC Curve</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Sensitivity and Specificity</topic><topic>Sexually transmitted diseases</topic><topic>STD</topic><topic>Tau protein</topic><topic>tau Proteins - blood</topic><topic>Vascular dementia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Shieh-Yueh</creatorcontrib><creatorcontrib>Chiu, Ming-Jang</creatorcontrib><creatorcontrib>Chen, Ta-Fu</creatorcontrib><creatorcontrib>Lin, Chin-Hsien</creatorcontrib><creatorcontrib>Jeng, Jiann-Shing</creatorcontrib><creatorcontrib>Tang, Sung-Chun</creatorcontrib><creatorcontrib>Lee, Yen-Fu</creatorcontrib><creatorcontrib>Yang, Che-Chuan</creatorcontrib><creatorcontrib>Liu, Bing-Hsien</creatorcontrib><creatorcontrib>Chen, Hsin-Hsien</creatorcontrib><creatorcontrib>Wu, Chau-Chung</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Shieh-Yueh</au><au>Chiu, Ming-Jang</au><au>Chen, Ta-Fu</au><au>Lin, Chin-Hsien</au><au>Jeng, Jiann-Shing</au><au>Tang, Sung-Chun</au><au>Lee, Yen-Fu</au><au>Yang, Che-Chuan</au><au>Liu, Bing-Hsien</au><au>Chen, Hsin-Hsien</au><au>Wu, Chau-Chung</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2017-08-24</date><risdate>2017</risdate><volume>7</volume><issue>1</issue><spage>9304</spage><epage>12</epage><pages>9304-12</pages><artnum>9304</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Immunomagnetic reduction (IMR), which involves the use of antibody-functionalized magnetic nanoparticles to specifically label target biomarkers, was utilized to develop an assay for total tau protein in human plasma. The analytic properties of the IMR assay on tau protein were investigated. The limit of detection was found to be 0.026 pg/ml. Other properties such as Hook effect, assay linearity, dilution recovery range, reagent stability, interference test, and spiked recovery were also characterized. The ultra-sensitive IMR assay was applied to detect the plasma tau protein levels of subjects with prevalent neurodegenerative diseases, such as Alzheimer’s disease (AD), mild cognitive impairment (MCI) due to AD, Parkinson’s disease (PD), frontotemporal dementia (FTD) and vascular dementia (VD). The concentrations of plasma tau protein in patients with VD, PD, MCI due to AD, FTD, and AD patients were higher than that of healthy controls. Using an ROC curve analysis, the cutoff value for discriminating dementia patients from healthy controls was 17.43 pg/ml, resulting in 0.856 and 0.727 for clinical sensitivity and specificity, respectively. The area under the ROC curve was 0.908. These results imply that the IMR plasma tau assay would be useful to screen for prevalent neurodegenerative diseases.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>28839167</pmid><doi>10.1038/s41598-017-09009-3</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2017-08, Vol.7 (1), p.9304-12, Article 9304 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5571227 |
| source | MEDLINE; Nature Free; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry; Springer Nature OA Free Journals |
| subjects | 631/378/340 631/61/32 9/10 Aged Aged, 80 and over Alzheimer's disease Cognitive ability Dementia Dementia disorders Diagnostic Tests, Routine - methods Feasibility Studies Frontotemporal dementia Humanities and Social Sciences Humans Mass Screening - methods Middle Aged Movement disorders multidisciplinary Nanoparticles Neurodegenerative diseases Neurodegenerative Diseases - diagnosis Parkinson's disease Plasma Plasma - chemistry Proteins ROC Curve Science Science (multidisciplinary) Sensitivity and Specificity Sexually transmitted diseases STD Tau protein tau Proteins - blood Vascular dementia |
| title | Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T08%3A46%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analytical%20performance%20of%20reagent%20for%20assaying%20tau%20protein%20in%20human%20plasma%20and%20feasibility%20study%20screening%20neurodegenerative%20diseases&rft.jtitle=Scientific%20reports&rft.au=Yang,%20Shieh-Yueh&rft.date=2017-08-24&rft.volume=7&rft.issue=1&rft.spage=9304&rft.epage=12&rft.pages=9304-12&rft.artnum=9304&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-017-09009-3&rft_dat=%3Cproquest_pubme%3E1932846658%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1957300451&rft_id=info:pmid/28839167&rfr_iscdi=true |